Page 2 - Solid Tumours News Today

European Medicines Agency validates marketing authorisation application for Jemperli plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer ... | April 25, 2023

The largest head-to-head trial of PD-1 inhibitors for non-squamous non-small cell lung cancer suggested dostarlimab with chemo aided survival.

Investegate announcements from Redx Pharma plc, RXC004 Phase 2 Combination Arms to Open Enrolment

The companies will aim to improve treatment for patients with prostate, breast and lung cancer - News - PharmaTimes

According to a recent study, a group of Wake Forest University School of Medicine researchers found a new way of treating solid tumours with the creation of a novel nanoparticle. They also discovered that cancers of breast, colon, head and neck have tumours that are solid. Scientists Discover New Way of Treating Solid Tumours Using Nanoparticles.

/PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...

For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab

If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer

Pembrolizumab and olaparib demonstrated antitumor activity and acceptable safety for men with prostate cancer.

Global Roundup: Singapore's AUM Biosciences Raises $27 Million in Series A Financing Round - read this article along with other careers information, tips and advice on BioSpace